About Darbepoetin alfa (ARANESP)
Class: | Erythropoiesis-Stimulating Agent (ESA)
Use: | Darbepoetin alfa (ARANESP) is used to treat anemia associated with chronic kidney disease (CKD) and anemia due to chemotherapy in patients with non-myeloid malignancies.
Adult dose: | For anemia due to CKD: Initial dose is 0.45 mcg/kg body weight administered as a single intravenous or subcutaneous injection once weekly or 0.75 mcg/kg once every two weeks. For anemia due to chemotherapy: Initial dose is 2.25 mcg/kg subcutaneously once week
Drug Class
Erythropoiesis-Stimulating Agent (ESA)
Uses & Indications
Darbepoetin alfa (ARANESP) is used to treat anemia associated with chronic kidney disease (CKD) and anemia due to chemotherapy in patients with non-myeloid malignancies.
Storage Requirements
Store in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light. Keep the prefilled syringe in the outer carton until ready to use.
Manufacturer & Packaging
Manufacturer: Amgen Europe B.V., NETHERLANDS
Package Size
0.3ml Pre-filled Syringe x 4
Price & Supplier
Price in UAE: AED 1797.50
Dosage Information
Adult Dose
For anemia due to CKD: Initial dose is 0.45 mcg/kg body weight administered as a single intravenous or subcutaneous injection once weekly or 0.75 mcg/kg once every two weeks. For anemia due to chemotherapy: Initial dose is 2.25 mcg/kg subcutaneously once weekly or 500 mcg once every three weeks.
Pediatric Dose
For pediatric patients with CKD: Initial dose is 0.45 mcg/kg body weight administered as a single intravenous or subcutaneous injection once weekly. Dosing adjustments should be made based on hemoglobin response.
Side Effects
Common side effects include hypertension, dyspnea, peripheral edema, cough, and injection site reactions.
Contraindications & Precautions
Contraindicated in patients with uncontrolled hypertension and in those who have shown hypersensitivity to darbepoetin alfa or any of its components.
Important Warnings
Increased risk of death, myocardial infarction, stroke, venous thromboembolism, and tumor progression or recurrence. Use the lowest dose sufficient to reduce the need for red blood cell transfusions. Monitor hemoglobin levels regularly. Use with caution in patients with a history of cardiovascular disease or thromboembolic events.
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice.
Always consult with a licensed healthcare provider or pharmacist in the UAE before taking any medication.
The information presented here is specific to medicines available in UAE pharmacies and is regularly updated
to ensure accuracy for patients and healthcare professionals in the United Arab Emirates.